Het gesprek met de patiënt is essentieel voor goede farmacotherapeutische zorg

Autor: Lidwien C. Lemmens, Gepke O. Delwel, Renske J. Hoefman, Judith D. de Jong, Marjolein Weda

Publikováno v: Tijdschrift voor Gerontologie en Geriatrie, Iss 2 (2018)

Kwetsbare ouderen met polyfarmacie lopen een groter risico op vermijdbare medicatie-gerelateerde gezondheidsschade. Ommedicatieveiligheid te verbeteren is door het zorgveld, in samenspraak met de IGZ, een aantal richtlijnen en veldnormen opgesteld me

Externí odkaz: https://doaj.org/article/db64a3dedd3440248459fb838bcd5c03

Het gesprek met de patiënt is essentieel voor goede farmacotherapeutische zorg

Autor: Renske J. Hoefman, Gepke O. Delwel, Judith D. de Jong, Marjolein Weda, Lidwien C. Lemmens

Publikováno v: Tijdschrift voor Gerontologie en Geriatrie. 49:56-59

Frail elderly with polypharmacy are at greater risk of preventable medication-related health damage. To improve medication safety, the healthcare field prepared, in consultation with the Dutch Health Care Inspectorate, a number of guidelines and stan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ec0d85dc2d854cfac8d04b627b7488e
https://doi.org/10.1007/s12439-018-0247-7

A baseline assessment by healthcare professionals of Dutch pharmacotherapeutic care for the elderly with polypharmacy

Autor: Gepke O. Delwel, Martine C. de Bruijne, Lutien Bakker, Cordula Wagner, Peter F. Kemper

Publikováno v: European Journal of Public Health, 27(4), 679-686. Oxford University Press
Bakker, L, Kemper, P F, Wagner, C, Delwel, G O & De Bruijne, M C 2017, ' A baseline assessment by healthcare professionals of Dutch pharmacotherapeutic care for the elderly with polypharmacy ', European Journal of Public Health, vol. 27, no. 4, pp. 679-686 . https://doi.org/10.1093/eurpub/ckx076

Background: Polypharmacy is common in the elderly population and is associated with an increased risk of adverse drug events. To diminish this risk, the guideline 'Polypharmacy in the Elderly' has been developed in 2012. This study examines, to what

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33e5d6607e8a571c21ede192b7a4e0e3
https://research.vumc.nl/en/publications/e5317785-1ad0-4bc2-b8aa-023293c2f6bd

Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands

Autor: Cornelis J. A. Punt, Adri Steenhoek, Margreet G. Franken, Jennifer G. Gaultney, Carin A. Uyl-de Groot, Chantal W. M. van Gils, Miriam Koopman, Gepke O. Delwel, Peter C. Huijgens, William K. Redekop, Wim G. Goettsch

Publikováno v: European Journal of Cancer, 49(1), 8-16. Pergamon
Franken, M G, van Gils, C W M, Gaultney, J G, Delwel, G O, Goettsch, W, Huijgens, P C, Steenhoek, A, Punt, C J A, Koopman, M, Redekop, W K & Uyl-de Groot, C A 2013, ' Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands ', European Journal of Cancer, vol. 49, no. 1, pp. 8-16 . https://doi.org/10.1016/j.ejca.2012.06.010
European Journal of Cancer, 49, 8-16. Elsevier Ltd.
European journal of cancer (Oxford, England, 49(1), 8-16. Elsevier Limited

Objective: To investigate the practical feasibility to develop evidence on drug use and cost-effectiveness in oncology practice. Patients and methods: Feasibility was examined using three Dutch case studies. Each case study investigated the degree of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cfb86fac83e95dfb4c5ebcd2cb8a48e
https://research.vumc.nl/en/publications/cfef1249-7dab-48bf-91b8-a195d8952f50

[Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement]

Autor: Ties, Hoomans, Nicole, van der Roer, Johan L, Severens, Gepke O, Delwel

Publikováno v: Nederlands tijdschrift voor geneeskunde. 154

For new drugs to be included in appendix 1B of the drug reimbursement system, they must have proven added therapeutic value, an acceptable budget impact, and be cost-effective. To validate the latter, pharmacoeconomic evaluations have become mandator

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0bafc93ca376dad8dc8b542f144995c9
https://pubmed.ncbi.nlm.nih.gov/20699045